首页> 美国卫生研究院文献>BMJ Case Reports >Novel treatment (new drug/intervention; established drug/procedure in new situation): A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy
【2h】

Novel treatment (new drug/intervention; established drug/procedure in new situation): A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy

机译:新型治疗(新药/干预;新情况下已确立的药物/治疗方法):采用局部抗炎治疗的新型治疗中心性浆液性脉络膜视网膜病变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A 45-year-old Caucasian female with diagnosis of central serous chorioretinopathy (CSCR) did not improve on conventional observational approach. She was not willing to proceed with photocoagulation or photodynamic therapy. An unconventional approach of topical anti-inflammatory (ketorolac, dexamethasone and hydrocortisone) preparation was prescribed. The course of her CSCR responded well on this unconventional treatment, but relapsed on cessation or tapering of treatment. After 18 weeks of treatment with a gradual taper, her condition resolved. The present case highlights an alternative but unconventional treatment of CSCR with prolonged use of anti-inflammatories.
机译:一名诊断为中心性浆液性脉络膜视网膜病变(CSCR)的45岁白人女性在常规观察方法上未见改善。她不愿意进行光凝或光动力疗法。规定了一种非常规的局部抗炎(酮咯酸,地塞米松和氢化可的松)制剂。她的CSCR疗程对该非常规治疗反应良好,但因停止治疗或逐渐减少治疗而复发。经过逐渐渐缩的治疗18周后,她的病情得到了缓解。本案强调了长期使用抗炎药对CSCR的替代性而非常规治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号